---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-26-000003"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:04:36.835523+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zentalis updates azenosertib program; DENALI Part 2 topline readout expected by year-end 2026

## Summary
- Completed enrollment in DENALI Part 2a, supporting registration-intended development of azenosertib.
- Aligned with FDA on confirmatory ASPENOVA Phase 3 trial design for Cyclin E1-positive PROC.
- Cash, equivalents and securities of $280.7M as of Sep 30, 2025; runway into late 2027.
- 2026 milestones: Part 2a dose confirmation H1, ASPENOVA initiation H1, Part 2 topline by YE.
- DENALI Part 2, if successful, could support accelerated approval for azenosertib in PROC.

## SEC filing metadata
- accession: 0001725160-26-000003
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000003/0001725160-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000003/zntl-20260106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-26-000003
- JSON: https://secwatch.observer/filing/0001725160-26-000003.json
- Plain text: https://secwatch.observer/filing/0001725160-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.